This session will cover different perspectives of translational science and new models of asset development for University based intellectual property. Panelists include senior executives of two different models of development, one a for profit investment fund directly managed by faculty members of Stanford University , the other a wholly owned non-profit drug development subsidiary of Emory University.
Felmont F. Eaves, MD, FACS
Founder, EMRGE, LLC
Professor of Surgery, Emory University School of Medicine
Director, Emory Aesthetic Center
Assistant Vice President for Research and Real Estate
Executive Director, Emory Innovations, Inc.
Geoffrey C. Gurtner, MD, FACS
Johnson and Johnson Professor of Surgery, Stanford University
Professor, by Courtesy, of Materials Science and Engineering, Stanford University
Managing Partner, Tautona Group
George R. Painter, Ph.D.
CEO, Drug Innovation Ventures at Emory, LLC (DRIVE) and Director, Emory Institute for Drug Development (EIDD)